[ad_1]
Investing.com – Regeneron Pharma (NASDAQ:) reported on Wednesday first quarter that beat analysts’ forecasts and income that topped expectations.
Regeneron Pharma introduced earnings per share of $11.49 on income of $2.97B. Analysts polled by Investing.com anticipated EPS of $9.72 on income of $2.69B.
Regeneron Pharma shares are down 33.79% from the start of the 12 months and are buying and selling at $660.49 , down-from-52-week-high.They’re under-performing the which is down 19.69% 12 months up to now.
Regeneron Pharma follows different main Healthcare sector earnings this month
Regeneron Pharma’s report follows an earnings beat by J&J on Tuesday, April 19, 2022, who reported EPS of $2.67 on income of $23.43B, in comparison with forecasts EPS of $2.59 on income of $23.62B.
UnitedHealth had beat expectations on Thursday, April 14, 2022 with first quarter EPS of $5.49 on income of $80.15B, in comparison with forecast for EPS of $5.36 on income of $78.73B.
Keep up-to-date on the entire upcoming earnings stories by visiting Investing.com’s earnings calendar
[ad_2]
Source link